Tg(TRE-MAX*)
| Status | Available to order |
| EMMA ID | EM:15980 |
| Citation information | RRID:IMSR_EM:15980 Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information. |
| International strain name | Tg(TRE-MAX*) |
| Alternative name | TREMax* |
| Strain type | Transgenic Strains |
| Allele/Transgene symbol | Tg(TRE-Max*) |
| Gene/Transgene symbol | Tg(TRE-Max*) |
Information from provider
| Provider | Fabio GIUNTINI |
| Provider affiliation | VHIO |
| Genetic information | Transgenic mouse line expressing the human MAX* protein under the control of a tetracycline-responsive element (TRE). Requires a tTA or rtTA transactivator for inducible expression of MAX*. The construct uses a standard tetracycline-responsive promoter compatible with the Tet-On system. It enables inducible expression of the human MAX* protein, which may be used to evaluate therapeutic strategies targeting MYC activity, a key driver in many human cancers. The expressed MAX* protein sequence is derived from the human MAX sequence. It comprises a part of the human p21-MAX coding sequence, specifically encoding the bHLHZip domain required for dimerization and DNA binding. The expressed amino-acid sequence is: MADKRAHHNALERKRRDHIKDSFHSLRDSVPSLQGEKASRAQILDKATEYIQYMRRKNHTHQQDIDDLKRQNALLEQQVRALE. The asterisk in the "MAX*" symbol denotes the addition of an initiating methionine (start) codon in the expressed sequence that is not present in the native coding sequence. |
| Phenotypic information | Homozygous:Mice homozygous for the TRE-MAX* transgene are not viable, suggesting embryonic or early postnatal lethality potentially due to leaky or excessive expression of the MAX* protein.Heterozygous:Mice heterozygous (hemizygous) for the TRE-MAX* transgene are viable and fertile. They display no overt phenotype in the absence of a tetracycline transactivator (e.g., rtTA), allowing for regulated expression upon induction. |
| Breeding history | Originally generated via pronuclear injection on a mixed C57BL/6 and FVB/N background. Maintained by heterozygous x wild-type crosses to preserve the transgene. Backcrossed intermittently to C57BL/6 and FVB/N to sustain colony vigor and transgene expression consistency. |
| References | None available |
| Homozygous fertile | no |
| Homozygous viable | no |
| Homozygous matings required | no |
| Immunocompromised | no |
Information from EMMA
| Archiving centre | CNB-CSIC, Centro Nacional de Biotecnologia, Madrid, Spain |
| Animals used for archiving | heterozygous males |